---
title: "QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295698010.md"
description: "The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T18:25:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295698010.md)
  - [en](https://longbridge.com/en/news/295698010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295698010.md)
generator: "portal-rs"
---

# QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024

The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [AKYA.US](https://longbridge.com/en/quote/AKYA.US.md)
- [QTRX.US](https://longbridge.com/en/quote/QTRX.US.md)

## Related News & Research

- [Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test](https://longbridge.com/en/news/296029225.md)
- [QTRX: Revenue up 34% year-over-year, but 2026 outlook lowered amid market softness and execution challenges](https://longbridge.com/en/news/295406519.md)
- [Quanterix Q2 revenue rises 34% but cuts 2026 outlook](https://longbridge.com/en/news/295405279.md)
- [Quanterix Warns of Broad Risk Exposure Despite No New Material Changes in Latest 10-Q](https://longbridge.com/en/news/295494435.md)
- [Quanterix management participates in Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/295105437.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**